Meeting
2019 ASCO Annual Meeting
ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3rd/4th line colorectal cancer.
Authors
Tony R. Reid
University of California, San Diego, San Diego, CA
Tony R. Reid , George A. Fisher Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02096354
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3526)
DOI
10.1200/JCO.2019.37.15_suppl.3526
Abstract #
3526
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.
First Author: Tony R. Reid
Poster
2023 ASCO Annual Meeting
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).
First Author: Patrick M Boland
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland
Poster
2016 ASCO Annual Meeting
Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).
First Author: Emmanuelle Samalin